



NEWS UPDATE

NCI Anal Cancer Prevention Study Begins Enrolling Patients *The EMMES Corporation Will Coordinate the Clinical Trial*

Rockville, MD – September 23, 2014 – With the support of The EMMES Corporation, clinical investigators from the AIDS Malignancy Consortium (AMC) are preparing to enroll HIV-infected men and women throughout the United States and Puerto Rico in a major investigation of a prevention strategy for anal cancer. The study will enroll over 5,000 participants who are HIV-infected and who have pre-cancerous lesions. EMMES will provide operations, data management, site monitoring, and regulatory support under the eight-year, \$89 million award. The study is scheduled to begin enrollment this month.

The Anal Cancer/HSIL Outcomes Research Study, or ANCHOR, will determine the effectiveness of treating anal high-grade squamous intraepithelial lesions for anal cancer prevention. Study participants will be randomized into two groups: either to receive treatment for pre-cancerous lesions with current options used in clinical practice, or to be monitored closely for progression to cancer without treatment. Both groups will be evaluated every six months for up to five years, and will be compared on the incidence of cancer in each group.

EMMES' role is to coordinate the research, which encompasses data capture, site monitoring, and regulatory compliance, as well as providing general operational support to the research team.

The National Cancer Institute is funding the trial through a cooperative agreement with UCLA. The protocol chairman and the ANCHOR coordinating center are based at the University of California, San Francisco.

“Our ultimate goal is that the study will determine whether the treatment of pre-cancerous lesions reduces the risk of developing anal cancer,” said Don Vena, the principal investigator for EMMES. “The protocol chair, Dr. Joel Palefsky, is considered a pioneer of this field, and we’re honored to work with him on this landmark study.”

About The EMMES Corporation

EMMES is a professional partner to clinicians, scientists, and program leaders around the world. Founded in 1977, the company provides scientific and technical support for clinical research studies funded by industry, foundations and government agencies. EMMES has more than 400 employees whose specialties range from biostatistics and bioinformatics to safety surveillance and monitoring to data management and information technology. Its staff is committed to the highest quality of research, evidenced by numerous major scientific publications and presentations. In addition to its headquarters in Rockville, MD, the company has offices in Canada and India. For more information, visit www.emmes.com.

For More Information

Contacts:

Company: Brian Hochheimer
The EMMES Corporation
301-251-1161
bhochheimer@emmes.com

Media: Karen Vahouny
703-624-2674
kvahouny@gmail.com